Middle East Pharmaceutical Industries Company (TADAWUL: 4016)

Market Cap	2.45B
Revenue (ttm)	387.18M
Net Income (ttm)	80.44M
Shares Out	20.00M
EPS (ttm)	4.02
PE Ratio	30.43
Forward PE	24.98
Dividend	1.50 (1.22%)
Ex-Dividend Date	Sep 2, 2024

Volume	43,987
Open	122.20
Previous Close	122.60
Day's Range	122.20 - 123.40
52-Week Range	90.20 - 197.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2024

About Middle East Pharmaceutical Industries Company

Middle East Pharmaceutical Industries Company engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. The company operates through three segments: Private, Public, and Export. It offers medicines and preparations used to treat skin diseases, skin creams, and skin care products; respiratory, central nervous, digestive, and musculoskeletal system medicines; urinary and reproductive system drugs; disinfectants; and various therapeutic ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 543
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4016

Financial Performance

In 2023, Middle East Pharmaceutical Industries Company's revenue was 338.44 million, an increase of 11.82% compared to the previous year's 302.66 million. Earnings were 65.83 million, an increase of 10.72%.